Sign In
Buy PHAT
$10.09
+0.440 (+4.56%)
At Close: Jun 03, 2026
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
07:45am, Tuesday, 31'st Aug 2021
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
07:30am, Thursday, 05'th Aug 2021
FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
08:30am, Monday, 02'nd Aug 2021
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
04:01pm, Tuesday, 25'th May 2021
FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
08:00am, Tuesday, 11'th May 2021
FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
05:48pm, Thursday, 06'th May 2021
FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
05:46am, Wednesday, 07'th Apr 2021
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
Why Mustang Bio, Phathom Pharma And More Are Moving Today
11:37am, Tuesday, 02'nd Feb 2021
Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the fir
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
08:30am, Tuesday, 19'th Jan 2021
FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
08:00am, Thursday, 07'th Jan 2021
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
06:43pm, Wednesday, 16'th Dec 2020
FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
04:01pm, Tuesday, 15'th Dec 2020
FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
08:30am, Monday, 14'th Dec 2020
Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss N
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
04:05pm, Monday, 30'th Nov 2020
Topline results expected in second half of 2021 Topline results expected in second half of 2021
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
08:00am, Friday, 27'th Nov 2020
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea
